Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L

J Thorac Oncol. 2018 Jul;13(7):e113. doi: 10.1016/j.jtho.2018.02.004.

Authors

Julie Niogret¹, Bruno Coudert¹, Romain Boidot²

Affiliations

¹ Department of Medical Oncology, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France.
² Platform of Transfer in Cancer Biology, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France; GIMI Genetic and Immunology Medical Institute, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France. Electronic address: rboidot@cgfl.fr.

PMID: 29935845
DOI: 10.1016/j.jtho.2018.02.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Afatinib / pharmacology*
Aged
Drug Resistance, Neoplasm*
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology*
Mutation*
Prognosis
Protein Kinase Inhibitors / pharmacology*

Substances

Protein Kinase Inhibitors
Afatinib
EGFR protein, human
ErbB Receptors